文献
J-GLOBAL ID:202002219817028560
整理番号:20A1066783
低プログラム死リガンド1閾値を有する非小細胞肺癌に対するファーストライン単独療法としてのペンブロリムマブ【JST・京大機械翻訳】
Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold
著者 (7件):
Xu Zhijie
(Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China)
,
Xu Zhijie
(National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China)
,
Wang Xiang
(Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China)
,
Chen Xi
(Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China)
,
Zeng Shuangshuang
(Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China)
,
Gong Zhicheng
(Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China)
,
Yan Yuanliang
(Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China)
資料名:
Journal of Cell Communication and Signaling
(Journal of Cell Communication and Signaling)
巻:
14
号:
1
ページ:
129-130
発行年:
2020年
JST資料番号:
W4536A
ISSN:
1873-9601
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
ドイツ (DEU)
言語:
英語 (EN)